Mainz Biomed B.V. (MYNZ)
USD 3.2
(4.08%)
USD 3.2
(4.08%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.19 Million USD | 15.43% |
| 2022 | 1.9 Million USD | -18.28% |
| 2021 | 2.32 Million USD | -14.19% |
| 2020 | 2.71 Million USD | 22.95% |
| 2019 | 2.2 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q4 | 2.19 Million USD | -8.52% |
| 2023 Q2 | 2.54 Million USD | 15.17% |
| 2023 Q1 | 2.2 Million USD | 16.15% |
| 2023 Q3 | 2.4 Million USD | -5.68% |
| 2023 FY | 2.19 Million USD | 15.43% |
| 2022 Q2 | 1.36 Million USD | 0.0% |
| 2022 Q4 | 1.9 Million USD | 0.0% |
| 2022 FY | 1.9 Million USD | -18.28% |
| 2021 Q1 | 485.02 Thousand USD | -82.12% |
| 2021 FY | 2.32 Million USD | -14.19% |
| 2021 Q3 | 485.02 Thousand USD | -80.4% |
| 2021 Q4 | 2.32 Million USD | 379.95% |
| 2021 Q2 | 2.47 Million USD | 410.18% |
| 2020 FY | 2.71 Million USD | 22.95% |
| 2020 Q4 | 2.71 Million USD | 379.0% |
| 2020 Q3 | 566.35 Thousand USD | 0.0% |
| 2020 Q2 | 566.35 Thousand USD | 0.0% |
| 2020 Q1 | 566.35 Thousand USD | 26.67% |
| 2019 FY | 2.2 Million USD | 0.0% |
| 2019 Q4 | 447.1 Thousand USD | 0.0% |
| 2019 Q1 | 447.1 Thousand USD | 0.0% |
| 2019 Q2 | 447.1 Thousand USD | 0.0% |
| 2019 Q3 | 447.1 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 3.07 Million USD | 28.566% |
| Applied DNA Sciences, Inc. | 739.16 Thousand USD | -197.078% |
| Aspira Women's Health Inc. | 1.43 Million USD | -53.559% |
| Biodesix, Inc. | 35.22 Million USD | 93.766% |
| BioNexus Gene Lab Corp. | 98.76 Thousand USD | -2123.392% |
| bioAffinity Technologies, Inc. | 1.11 Million USD | -96.33% |
| bioAffinity Technologies, Inc. | 1.11 Million USD | -96.33% |
| Bionano Genomics, Inc. | 7.17 Million USD | 69.395% |
| CareDx, Inc | 28.27 Million USD | 92.235% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Castle Biosciences, Inc. | 14.19 Million USD | 84.534% |
| DarioHealth Corp. | 24.59 Million USD | 91.07% |
| Exact Sciences Corporation | 2.47 Billion USD | 99.911% |
| Fulgent Genetics, Inc. | 10.11 Million USD | 78.282% |
| Guardant Health, Inc. | 1.13 Billion USD | 99.807% |
| ICON Public Limited Company | 3.66 Billion USD | 99.94% |
| IDEXX Laboratories, Inc. | 622.88 Million USD | 99.647% |
| Illumina, Inc. | 1.48 Billion USD | 99.853% |
| Intelligent Bio Solutions Inc. | 81.32 Thousand USD | -2600.173% |
| iSpecimen Inc. | 29.13 Thousand USD | -7438.239% |
| Standard BioTools Inc. | 3.98 Million USD | 44.868% |
| MDxHealth SA | 35.56 Million USD | 93.826% |
| 23andMe Holding Co. | 67.84 Million USD | 96.763% |
| Medpace Holdings, Inc. | 142.12 Million USD | 98.455% |
| Myriad Genetics, Inc. | 130.9 Million USD | 98.322% |
| ENDRA Life Sciences Inc. | 192.06 Thousand USD | -1043.323% |
| NeoGenomics, Inc. | 606.06 Million USD | 99.638% |
| Neogen Corporation | 888.39 Million USD | 99.753% |
| Inotiv, Inc. | 399.4 Million USD | 99.45% |
| Natera, Inc. | 282.94 Million USD | 99.224% |
| OpGen, Inc. | 2.02 Million USD | -8.62% |
| OPKO Health, Inc. | 222.03 Million USD | 99.011% |
| Psychemedics Corporation | 945 Thousand USD | -132.369% |
| Prenetics Global Limited | 867.21 Thousand USD | -153.212% |
| Prenetics Global Limited | 867.21 Thousand USD | -153.212% |
| Precipio, Inc. | 106 Thousand USD | -1971.593% |
| Personalis, Inc. | 1.23 Million USD | -77.949% |
| RadNet, Inc. | 812.06 Million USD | 99.73% |
| Sera Prognostics, Inc. | 840 Thousand USD | -161.415% |
| Sotera Health Company | 2.22 Billion USD | 99.901% |
| Neuronetics, Inc. | 59.28 Million USD | 96.296% |
| Star Equity Holdings, Inc. | 1.14 Million USD | -91.781% |
| Star Equity Holdings, Inc. | 1.14 Million USD | -91.781% |
| Trinity Biotech plc | 54.65 Million USD | 95.982% |
| T2 Biosystems, Inc. | 6.59 Million USD | 66.719% |
| Twist Bioscience Corporation | 79.17 Million USD | 97.226% |
| Exagen Inc. | 19.23 Million USD | 88.582% |